乳腺癌术后肺转移39例临床分析.pdf

现代肿瘤医学2015年08月第23卷第15期 MODERN ONCOLOGY,Aug-2015,VOL.23,NO.15
2141
[ 11] Gronbog BH, Bremnes RM, Flotten O, et al. Phase l study by the
chemotherapy: Etoposide combined with oxaliplatin or cisplatin
Norwegian lung cancer study group: Pemetrexed plus carboplatin
regimens in the treatment of extensive-stage small cell lung canc-
compared with gemcitabine plus carboplatinas first- line chemo-
er in elderly patients[ J]. Chinese J Lung Cancer, 2013, 16(1)
leray in advanced non-small-cell lung cancer[ J]. J Clin On
20-22.[蒲丹,侯梅,李之曦,等.奥沙利铂或顺铂联合足叶
col,2009,27(19):3217-3221
乙甙治疗老年广泛期小细胞肺癌的随机对照临床研究[J].
I 12] Li Jingjing. Observation on the clinical effici of pemetrexed com-
中国肺癌杂志,2013,16(1):20-22.]
bined with oxaliplatin in the treatment of advanced non-small [14 Huang XE, Tian GY, Cao J, et al. Pemetrexedasa component of
cell lung cancer[ J]. Chinese J Hospital Pharmacy, 2013, 33(8):
finst-, second -and third-line chemotherapy in treating p
625-627,[李静静,培美曲塞联合奥沙利铂治疗晚期非小细
tients with metastatic lung adenocarcinoma J]. Asian Pac
胞肺癌的临床观察[J],中国医院药学杂志,2013,33(8):625
Cancer Prey,2013,14(11):663-6667
(编校:徐萌
[ 13] Pu Dan, Hou Mei, Li Zhixi, et al. A randomized controlled study of
乳腺癌术后肺转移39例临床分析
ト智斌,李娟,王勇,赵渭东,宋少伟,张永辉,李锋,李晓辉,白欣
Pulmonary metastasis of breast cancer operation: A Clinical analysis of 39 cases
Bu Zhibin, Li Juan, Wang Yong, Zhao Weidong, Song Shaowei, Zhang Yonghui, Li Feng, Lixiaohui, Bai Xin
Department of Tumor Surgery, Central Hospital Weinan City, Shaanxi Weinan 714000, China
(Abstract] Objective: To discuss the postoperative pulmonary metastasis of breast cancer clinical pathological
characteristics, treatments and progostic factors. Methods: Collected clinical data of 39 patients with pulmonary me-
tastasis of breast cancer to analyze the clinical characteristics, treatment and prognosis. Results: Pulmonary metastasis
of breast carcinoma after operation time was 9-159 months, and the average time was(41.5+11)months. Th
currence of pulmonary metastasis time have a relationship with the size of tumor, pathologic type, Her-2 expression
and the postoperative chemotherapy(P <0.05). The median survival of patients with pulmonary metastasis was 19
months (4-57 months). The 1, 2, 3, 5-year survival rates were 84.61%, 61. 53%0, 41. 02% and 7.69% respec-
tively. The number of pulmonary metastasis, maximum diameter, other organ metastasis, and treatments are associated
with the prognosis of patients(P<0.05). Conclusion: The prognosis of the patients with pulmonary metastasis of
breast cancer is associated with the number of pulmonary metastases, maximum diameter, other organ metastasis and
the treatments For postoperative pulmonary metastasis of breast cancer patients with operation indications, we should
give surgical treatment, and comprehensive treatment
Key words ] breast cancer; pulmonary metastasis; treatment
Modern Oncology2015,23(15):2141-2144
【摘要】目的:讨论乳腺癌术后肺转移临床病理特点、治疗方法及预后因素。方法:收集2000年1月-2009
年12月39例乳腺癌肺转移患者的临床资料,分析临床特点、治疗方法和预后。结果:乳腺癌术后肺转移的时
间9-159月,平均时间(41.5t11)月。肺转移发生时间与患者肿瘤大小病理类型、Her-2表达、术后化疗
关(P<0.05)。肺转移患者中位生存期19个月(4-57个月)。1、2、3、5年生存率分别为84.61%、
61.53%41.02%和7.69%。肺转移数目、最大直径、合并其他器官转移、治疗手段与患者的预后相关(P
<0.05)。结论:乳腺癌术后肺转移患者的预后与肺转移瘤数目、最大直径、合并其他器官转移、治疗手段相
关,对于有手术指征的乳腺癌术后肺转移患者首选手术治疗,综合治疗有较好的效果。
关